SuperworthHumacyte market cap HUMA
Share price times shares outstanding: what the whole company sells for, since 2020.
- Today, Oct 23, 2026
- $121M
- Highest close in our data
- $1.1B
- Nov 2021
Humacyte is worth $121M at the close on Oct 23, 2026, at $0.44 a share.
That is down 55% over the last year and up 3% over five years.
Its highest close in our data was $1.1B in Nov 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $121M | $112.6M | $299.7M | −40% |
| 2025 | $200.4M | $184.6M | $641.9M | −71% |
| 2024 | $692.2M | $270.3M | $982.4M | +135% |
| 2023 | $294.2M | $207.9M | $476.3M | +35% |
| 2022 | $217.6M | $217.6M | $759.1M | −71% |
| 2021 | $746.8M | $117M | $1.1B | +471% |
| 2020 | $130.7M | $126.1M | $130.7M | n/a |
Against its peers
Companies in Healthcare nearest Humacyte's size, closest first, today.
| Company | Market cap |
|---|---|
| HUMAHumacyte | $121M |
| KEQUKewaunee Scientific | $94.9M |
| ICCCImmucell | $93.1M |
| LFVNLifevantage | $73.4M |
| PDEXPro DEX | $199.3M |
| PLXProtalix BioTherapeutics | $205.5M |
| NATRNatures Sunshine Products | $213.8M |
| ELMDElectromed | $220.6M |
| SPROSpero Therapeutics | $64.6M |
| UTMDUtah Medical Products | $236.3M |
| APTAlpha Pro Tech | $56.7M |
| Peer median | $147.1M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Humacyte
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.